Given the similarities between COVID-19 pneumonitis, sepsis, and bacterial respiratory infection and with commonalities in underlying pathophysiology, this suggests IL6RA as a potentially broad therapeutic target for patients unwell with critical infection. Here, IL6R is linked to pneumonitis.